Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Joaquin F. Mould-Quevedo"'
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 82-87 (2024)
ABSTRACTBackground Cell-based quadrivalent influenza vaccines (QIVc) can increase effectiveness against seasonal influenza by avoiding mismatch from egg adaption of vaccine viruses. This study evaluates the population-level cost-effectiveness and imp
Externí odkaz:
https://doaj.org/article/75c97e014fc449a4872f595eb165ee12
Autor:
David Fisman, Norberto Giglio, Myron J. Levin, Van Hung Nguyen, Stephen I. Pelton, Maarten Postma, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F. Mould-Quevedo
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults
Externí odkaz:
https://doaj.org/article/46ed3c1277e545b39589949ace3de340
Autor:
Van Hung Nguyen, Pascal Crépey, Jean Marie Pivette, Ethan Settembre, Sankarasubramanian Rajaram, John Youhanna, Aimee Ferraro, Cheng Chang, Josephine van Boxmeer, Joaquin F. Mould-Quevedo
Publikováno v:
Vaccines, Vol 12, Iss 10, p 1161 (2024)
Background: Self-amplifying mRNA vaccines have the potential to increase the magnitude and duration of protection against COVID-19 by boosting neutralizing antibody titers and cellular responses. Methods: In this study, we used the immunogenicity dat
Externí odkaz:
https://doaj.org/article/82a35c5b96854c758f328da609d53e03
Autor:
Juan Garduño-Espinosa, Fortino Solórzano-Santos, Guillermo Salinas-Escudero, Guadalupe Miranda-Novales, Joaquin F. Mould-Quevedo, Diana Avila-Montiel
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
Externí odkaz:
https://doaj.org/article/ff3e8981efc7463388117db1fe000d99
Autor:
Marc Paccalin, Gaëtan Gavazzi, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin F. Mould-Quevedo
Publikováno v:
Vaccines, Vol 12, Iss 6, p 574 (2024)
Background: In France, influenza accounts for an average of over one million consultations with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over-65s. This study evaluates the cost-effectiveness of the adjuvanted qua
Externí odkaz:
https://doaj.org/article/131cc94a7cc44a68a7a4edf1e30dea29
Publikováno v:
Vaccines, Vol 11, Iss 10, p 1594 (2023)
Cell-based manufacturing of seasonal influenza vaccines eliminates the risk of egg-adaptation of candidate vaccine viruses, potentially increasing vaccine effectiveness (VE). We present an overview of published data reporting the VE and cost-effectiv
Externí odkaz:
https://doaj.org/article/621e56fa574a4ef2a200b9c39dfd8db7
Publikováno v:
Vaccines, Vol 11, Iss 10, p 1525 (2023)
Influenza can exacerbate underlying medical conditions. In this study, we modelled the potential impact of an egg-based quadrivalent influenza vaccine (QIVe) or adjuvanted QIV (aQIV) on hospitalizations and mortality from influenza-related cardiovasc
Externí odkaz:
https://doaj.org/article/0e8dd6d7cd8f45bf9372b8561e3e8f53
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
Co-circulation of influenza and SARS-CoV-2 has the potential to place considerable strain on health-care services. We estimate the cost-effectiveness and health-care resource utilization impacts of influenza vaccination of low-risk 50–64-y-olds in
Externí odkaz:
https://doaj.org/article/c250a592026846698829e9b9656aa9f2
Autor:
Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Michael Drummond, Milton C. Weinstein
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4603-4610 (2021)
In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged 65 years and older but only aQIV is reimbursed by the National Health Service (NHS). The objectiv
Externí odkaz:
https://doaj.org/article/35b1566157c44197be5c7944183a51c6
Publikováno v:
Vaccines, Vol 11, Iss 5, p 933 (2023)
Background: Enhanced vaccines (e.g., containing adjuvants) have shown increased immunogenicity and effectiveness in older adults, who often respond sub-optimally to conventional influenza vaccines. In this study, we evaluated the cost-effectiveness o
Externí odkaz:
https://doaj.org/article/04844c140bc14b97b74319d6357cf655